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Aims Extracellular matrix remodelling has been implicated in a number of vascular conditions, including venous hypertension
and varicose veins. However, to date, no systematic analysis of matrix remodelling in human veins has been performed.
Methods
and results
To understand the consequences of venous hypertension, normal and varicose veins were evaluated using proteomics
approaches targeting the extracellular matrix. Varicose saphenous veins removed during phlebectomy and normal sa-
phenous veins obtained during coronary artery bypass surgery were collected for proteomics analysis. Extracellular
matrix proteins were enriched from venous tissues. The proteomics analysis revealed the presence of .150 extracel-
lular matrix proteins, of which 48 had not been previously detected in venous tissue. Extracellular matrix remodelling in
varicose veins was characterized by a loss of aggrecan and several small leucine-rich proteoglycans and a compensatory
increase in collagen I and laminins. Gene expression analysis of the same tissues suggested that the remodelling process
associated with venous hypertension predominantly occurs at the protein rather than the transcript level. The loss of
aggrecan in varicose veins was paralleled by a reduced expression of aggrecanases. Chymase and tryptase b1 were
among the up-regulated proteases. The effect of these serine proteases on the venous extracellular matrix was further
explored by incubating normal saphenous veins with recombinant enzymes. Proteomics analysis revealed extensive
extracellular matrix degradation after digestion with tryptase b1. In comparison, chymase was less potent and degraded
predominantly basement membrane-associated proteins.
Conclusion The present proteomics study provides unprecedented insights into the expression and degradation of structural
and regulatory components of the vascular extracellular matrix in varicosis.
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1. Introduction
Venous hypertension is among the most prevalent medical problems to-
day causing significant morbidity in a variety of clinical conditions
including portal venous hypertension, haemorrhoids, pelvic congestion
syndrome, nutcracker syndrome, varicose veins, and venous ulcers.1
While consequences of venous hypertension are apparent, its patho-
physiology and chronic effects on the vessel wall are poorly understood,
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limiting preventative and therapeutic options. Among the spectrum of
conditions associated with venous hypertension, varicose veins in the
lower extremities are the most studied because of their high prevalence
and easy access to tissue for analysis. Approximately 23% of adults in the
USA alone have varicose veins with significant impact on the quality of
life of the patients.2 There are numerous risk factors to the development
of varicose veins including obesity, trauma, and pregnancy; however,
genetic predisposition is probably the most important factor.3
Chronic venous reflux can lead to structural changes that ultimately
cause weakening of the venous wall, resulting in dilation and a tortuous
appearance. The extracellular matrix (ECM) is crucial for the structural
integrity of the vessel wall. Recent advances in proteomics techniques
make it feasible to characterize the composition of the ECM and its re-
modelling in disease.4 – 6 Our group has previously introduced novel
proteomics methods for the analysis of ECM in clinical samples: (i) A
proteomics method to characterize the arterial ECM resulting in the
discovery of novel glycoproteins in the human aorta7 and (ii) a
substrate-guided proteomics approach to relate the activity of specific
proteases to ECM degradation products in arteries and to identify no-
vel MMP targets.6,8 No systematic analysis of pathological ECM remod-
elling in response to venous hypertension has been performed thus far.
In the present study, we explore the differences in the ECM compos-
ition of normal saphenous veins (NSV) and varicose saphenous veins
(VSV), and provide unprecedented insights into the expression and
degradation of structural and regulatory components of the vascular
ECM in varicosis.
2. Methods
See http://cardiovascres.oxfordjournals.org for an expanded description of
the methods.
2.1 Subjects
The investigation conforms with the principles outlined in the Declaration of
Helsinki. Following approval from the Institutional Review Board at the Mas-
sachusetts General Hospital (IRB; protocol 2010P002776) and written in-
formed consent, varicose great saphenous vein specimens (n ¼ 6) were
surgically removed during stab incision phlebectomy at the knee level. Nor-
mal saphenous vein specimens (n ¼ 6) were obtained by surgical resection in
patients undergoing coronary artery bypass surgery; the segment of the sa-
phenous vein near the knee level was collected for analysis from each patient.
Clinical characteristics for all patients recruited for this study are summarized
in Supplementary material online, Table S1. Both cohorts were comparable
with regards to age and gender. All vein samples were immediately processed
following surgical removal, i.e. adipose tissue was trimmed and blood rinsed
using cold saline solution. Segments of the vein tissue from each patient were
either placed in formalin for subsequent histological analysis or snap frozen in
liquid nitrogen and stored at 2808C for future analysis.
2.2 ECM protein enrichment
Vein tissues were subjected to our sequential extraction procedure as
previously described.7 In brief, vessels were washed briefly with cold
PBS, incubated in 0.5 M sodium chloride (NaCl) plus proteinase and phos-
phatase inhibitors for 4 h, followed by decellularization using 0.08% SDS
and extraction of ECM proteins using 4 M guanidine hydrochloride
(GuHCl) for 48 h before processing for proteomics analysis. Details are
given in the Supplementary material online.
2.3 Mass spectrometry analysis
Before mass spectrometry analysis, tryptic peptides from processed NaCl
and GuHCl extracts were separated on a nanoflow LC system
(Thermo Fisher Scientific, Ultimate 3000 RSLC nano). For gel-LC-MS/MS
analysis, spectra were collected from an Orbitrap mass analyser
(LTQ-Orbitrap XL, Thermo Fisher Scientific) using full ion scan mode
over the mass-to-charge (m/z) range 450–1600. MS/MS was performed
on the top six ions in each MS scan using the data-dependent acquisition
mode with dynamic exclusion enabled. For in-solution LC-MS/MS analysis,
spectra were collected from a Q Exactive Plus instrument (Thermo Fisher
Scientific) using full MS mode over the mass-to-charge (m/z) range 350–
1600. MS/MS was performed on the top 15 ions in each MS scan using
the data-dependent acquisition mode with dynamic exclusion enabled.
For multiple reaction monitoring (MRM), the column was coupled to a tri-
ple quadrupole mass spectrometer (TSQ Vantage, Thermo Fisher Scientif-
ic) for scheduled measurement. Skyline software (version 2.6, MacCoss Lab
Software) was used to generate the transition list with predicted collision
energies as well as optimized transitions and retention times. A minimum of
four transitions were selected per peptide. Further details are given in the
Supplementary material online.
2.4 Cell culture of human saphenous vein
smooth muscle cells
Samples of saphenous veins were collected from patients undergoing elect-
ive coronary artery bypass graft surgery (n ¼ 6) at Leeds General Infirmary.
Saphenous vein smooth muscle cells (SMCs) were extracted and expanded
as detailed in the Supplementary material online. SMCs were seeded into
6-well tissue culture plates. Twenty-four hours after seeding, cells were ser-
um starved for 1 h. All treatments were for 24 h, and the following stimuli
were diluted in serum-free DMEM at the concentrations indicated: human
transforming growth factor beta-1 (TGFb-1, R&D systems) 10 ng/mL, re-
combinant mouse TNFa (R&D systems) 100 ng/mL, and a synthetic pep-
tide corresponding to human angiotensin II (Ang II, Sigma-Aldrich)
100 ng/mL. Changes in gene expression after stimulation were measured
by RT–qPCR using probes against the corresponding human targets (for
a list of all probes used, see Supplementary material online, Table S2).
2.5 In vitro digestion of NSV
NSV (n ¼ 5) were digested with recombinant human chymase (1 mg/mL,
R&D Systems) or tryptase b1 (250 ng/mL, R&D Systems) according to
the protocol supplied by the manufacturer. Controls were incubated in en-
zyme buffer without enzyme (n ¼ 5). After a buffer exchange, the digests
were analysed by proteomics as previously described.8 The proteins re-
leased after digestion were concentrated and separated by SDS–PAGE.
Gel separation of proteins facilitates the investigation of protein degrad-
ation as protein laddering results in peptide identifications across multiple
gel bands. The entire lane was excised, subjected to in-gel tryptic digestion,
and analysed by LC-MS/MS. Evidence of degradation (P, 0.05) was further
validated by western blotting.
2.6 Statistical analysis
The adjusted total ion current (TIC) was used for quantification of the in-
solution digest. Spectral counts were used for the in-gel digests. Unpaired
Student’s t-tests were used to compare protein abundance and gene ex-
pression between NSV and VSV. To compare the effect of different treat-
ments on human venous SMCs, an ANOVA with Dunnett’s correction was
used. Pieces of NSV from five different donors were incubated with recom-
binant enzymes. Paired Student’s t-tests were used to compare the release
of ECM proteins from the same NSV (n ¼ 5) with and without enzymatic
digestion. Quantitative heat maps were generated using MultiExperiment
Viewer software (MeV v4.9, TM4). For visualization purposes, all TIC values
were transformed to N(0,1) for each protein. The relative difference in nor-
malized spectral counts is represented by a colour gradient. No outliers
were removed. A P-value of ,0.05 was considered significant for all tests
used. For graphical representation, averages+ S.D. are shown, unless
otherwise specified in the corresponding figure legend.
J. Barallobre-Barreiro et al.420
3. Results
3.1 Clinical samples
NSV and VSV were used from 12 patients (n ¼ 6 per group). On in-
spection, VSV were abnormal in appearance demonstrating character-
istic dilation and tortuosity. NSV were obtained during coronary bypass
surgery and showed no tortuosity or luminal dilation on inspection.
Electronic medical records of each patient were reviewed for evidence
of chronic venous insufficiency including imaging examinations such as
ultrasound study of the lower extremities. Patients in the control group
did not have a history of chronic venous insufficiency or symptoms of
pain, swelling, and/or heaviness in the lower extremities. In contrast, all
patients in the VSV group had documented sonographic evidence of
chronic venous insufficiency and symptoms of pain, swelling, and heavi-
ness in the lower extremity. The diameter of the VSV collected for ana-
lysis at the knee level typically measured 5–6 mm with vein valve
closure times ranging from 5 to 7 s indicating significant venous reflux.
Both cohorts were comparable with regards to age and gender (see
Supplementary material online, Table S1). Prior to molecular analysis,
tissues obtained from patients were histologically evaluated to confirm
the presence of venous disease (Figure 1A). VSV demonstrated exten-
sive neointima formation with subendothelial fibrosis, wall thickening,
and luminal dilation. In contrast, venous tissue from the NSV group de-
monstrated normal architecture with no evidence of neointima forma-
tion or fibrosis. All tissue sections stained positive fora-smooth muscle
cell actin (SMA).
3.2 Discovery proteomics of the ECM
Following confirmation of tissue histology, sequential segments of the vein
tissue were processed for proteomic analysis (Figure 1B). Both VSV and
NSV were diced into small pieces and subjected to a three-step extraction
procedure as previously described.7 Vein samples were consecutively in-
cubated with 0.5 M NaCl, 0.08% SDS, and 4 M GuHCl to decellularize
and sequentially extract extracellular space proteins. Subsequently, two
proteomics workflows were applied: firstly, NaCl and GuHCl extracts
were separated by SDS–PAGE to reduce sample complexity; the entire
lane was divided into a series of gel bands; and proteomic analysis was per-
formed on each of them as previously described.7 Secondly, NaCl and
GuHCl extracts were subjected to an in-solution digest. This MS/MS da-
taset was deposited in a public repository for mass spectrometry data
(http://www.ebi.ac.uk/pride, project accession: PXD002555). The in-
solution digest method combined with a faster, more sensitive mass spec-
trometer resulted in the detection of 152 ECM proteins in the GuHCl ex-
tracts and 136 in the NaCl extracts, compared with 90 and 115,
respectively, in the gel-LC–MS/MS approach (see Supplementary material
online, Figure S1, including representative MS spectra).
3.3 ECM composition of veins
As expected by our subfractionation procedure, NaCl extracts were
enriched with proteins of the extracellular space and newly synthesized
ECM proteins, which are not heavily cross-linked in the interstitial
matrix (see Supplementary material online, Table S3). Fibulins,
ECM-associated peptidases, or fibril-associated collagens with an inter-
rupted triple helix (FACITs) were already solubilized by the incubation
with 0.5 M NaCl. GuHCl extracts instead contained predominantly less
soluble proteins such as network-forming collagens, proteins asso-
ciated with collagens, laminins, or large aggregating proteoglycans
(see Supplementary material online, Table S4). Differences in protein
identifications between GuHCl and NaCl extracts are highlighted in
Supplementary material online, Figure S2. Notably, 48 proteins were
identified for the first time in the venous ECM (Table 1; see Supplemen-
tary material online, Table S5 for an expanded version).
3.4 Proteomics comparison of NSV and
VSV
Overall, more differentially expressed proteins were identified in the
in-solution digest (Table 1; see Supplementary material online, Table
S5 for an expanded version) than in the gel-LC-MS/MS approach (see
Supplementary material online, Table S6), and more proteins were dif-
ferentially expressed in the GuHCl extracts than in the NaCl extracts
(Figure 1C). In the NaCl extracts, TGFb-induced protein ig-h3 (BGH3),
a marker of TGFb activity, and thrombospondin-1 (TSP1), a potent ac-
tivator of TGFb, were up-regulated in VSV. In the GuHCl extracts, col-
lagen I chains a-1 and a-2 (CO1A1 and CO1A2) and laminins b-1, b-2,
and g-1 (LAMB1, LAMB2, and LAMC1) were increased. Most regula-
tory ECM components, however, were reduced, in particular small
leucine-rich proteoglycans (SLRPs) that are responsible for collagen fi-
bril formation, and important for the proper formation of the vascular
ECM (Figure 2).
All collagens form triple helices, but resistance to tensile stress is of
particular importance in collagens that contribute to fibre formation.
Among these fibrillar collagens, collagens I, III, and V are abundant in
the vasculature.7 The increase of CO1A1 and CO1A2 (i.e. fibril-
forming collagens) in VSV was in contrast to other families of collagen,
which were generally decreased (Figure 3A). Evidence for the quantita-
tive accuracy of our proteomic method is the strong correlation (r .
0.9) between the abundance of different collagen subunits (Figure 3B).
Hydroxylation of collagen on prolines within X-Pro-Gly triplets is a
key process during fibre formation.9 On average, 96% of peptides be-
longing to fibrillar collagens contained this post-translational modifica-
tion. Hydroxylation was less abundant in other collagens (Figure 3C).
Although detectable, hydroxylated Pro-Hyp-Gly sequences, which
are targets for prolyl-3-hydroxylase,9 and hydroxylation of lysine10
were less common (see Supplementary material online, Figure S3).
No differences were observed in collagen hydroxylation between
NSV and VSV.
3.5 Validation with targeted proteomics
We took advantage of our MS data from different cardiovascular terri-
tories5 – 8 and selected additional proteotypic peptides for targeted
MRM analysis (see Supplementary material online, Figure S4 and Table
S7) to confirm the increase in LAMB2 and LAMC1, and the loss of dec-
orin (PGS2), asporin (ASPN), tubulointerstitial nephritis antigen-like
protein (TINAL), dermatopontin (DERM), vitronectin (VTNC), and ag-
grecan (PGCA) in VSV. The aforementioned increase of CO1A1 and
CO1A2 in VSV was also confirmed by MRM analysis (Figure 4A). The
accuracy of our MRM method was demonstrated by selecting two dif-
ferent proteotypic peptides for the same protein (Figure 4B). For most
proteins, the correlation between the two different peptides for the
same protein was high (i.e. r. 0.95). An exception was aggrecan, prob-
ably because the selected peptides were on opposite sites of a com-
mon aggrecanase cleavage site.
3.6 Validation by independent techniques
Gene expression analysis in the same tissues demonstrated that most
changes in ECM protein abundance were not accompanied by
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corresponding changes in gene expression (Figure 5A). Only the down-
regulation of mimecan (MIME) and aggrecan (PGCA) in VSV was
observed at the protein as well as the transcript level. The loss of
fibronectin (FINC, Table 1) and galectin-1 in VSV (see Supplementary
material online, Table S6) was corroborated by immunohistochemistry
(see Supplementary material online, Figure S5). Additional immunoblots
were performed for mimecan, fibronectin, TGFb-induced protein
ig-h3, gelsolin (GELS), and decorin to confirm the changes in protein
abundance (Figure 5B; see Supplementary material online, Figure S5
for quantification by densitometry). The down-regulation of mimecan
Figure 1 Characterization of human VSV and results from two different proteomics approaches. (A) NSV and VSV were stained with haematoxylin and
eosin, with Masson’s trichrome and with antibodies for a-smooth muscle actin (SMA). (B) ECM proteins of NSV (n ¼ 6) and VSV (n ¼ 6) were obtained
using our previously published extraction procedure and analysed by LC-MS/MS after separation by gel-LC-MS/MS or in-solution digestion. (C) Com-
parison of differential protein expression in NSV and VSV by gel- and in-solution LC-MS/MS.
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was further validated by using venous human SMCs stimulated with
TGFb-1, TNFa, or Ang II. TGFb-1 and TNFa, but not Ang II, were
able to induce a repression of mimecan gene expression (Figure 5C).
3.7 Proteolytic degradation of the venous
ECM
Apart from collagen I and laminins, many ECM proteins were down-
regulated in the GuHCl fraction of VSV compared with NSV, including
the large aggregating proteoglycan aggrecan. Gene expression analysis
demonstrated that aggrecanases from the ADAMTS (a disintegrin
metalloproteinase with thrombospondin domains) family (ADAMTS1,
4, 5) are expressed in veins as well as venous SMCs (Figure 6A). Along
with aggrecan, transcript levels for ADAMTS1 and ADAMTS4 were
reduced in VSV (Figure 6B). Other proteases screened and the
protease inhibitor TIMP3 did not show a significant change.
Thus, we searched for additional proteases in our proteomics data-
set. Two mast cell proteases were identified in VSV: chymase and tryp-
tase b1. Both tryptase b1 and chymase could be localized in the
neointima of VSV. However, the staining pattern revealed a different lo-
calization within the vessel wall. Tryptase b1-positive cells were mainly
localized in the adventitia of the vessel wall, whereas chymase staining
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Table 1 ECM proteins with differential abundance between NSV and VSV based on in-solution digests
Full name Uniprot entry NSV (Av+ SD) VSV (Av+ SD) Fold change P-value Extract
Aggrecan PGCA_HUMAN 29.9+21.2 1.8+2.9 0.06 0.009 GuHCl
Asporin ASPN_HUMAN 207.1+132.3 41.0+31.6 0.20 0.014 GuHCl
Biglycan PGS1_HUMAN 1182.9+205.2 442.9+255.7 0.37 ,0.001 GuHCl
Cartilage intermediate layer protein 1 CILP1_HUMAN 5.9+2.0 2.1+2.9 0.35 0.025 GuHCl
Cathepsin D CATD_HUMAN 1.3+1.3 – NA NA GuHCl
Chondroitin sulfate proteoglycan 4 CSPG4_HUMAN – 1.2+1.1 NA NA NaCl
Clusterin CLUS_HUMAN 36.4+11.5 11.3+8.9 0.31 0.002 GuHCl
Collagen alpha-1(I) CO1A1_HUMAN 790.5+277.5 2017.0+585.5 2.55 0.001 GuHCl
Collagen alpha-1(III) CO3A1_HUMAN 13.7+10.4 3.5+3.1 0.25 0.043 NaCl
Collagen alpha-2(I) CO1A2_HUMAN 457.9+168.6 1129.7+367.0 2.47 0.002 GuHCl
Collagen alpha-2(IV) CO4A2_HUMAN 144.7+51.4 84.9+9.1 0.59 0.019 GuHCl
Collagen triple helix repeat-containing protein 1 CTHR1_HUMAN 4.5+4.5 – NA NA GuHCl
Decorin PGS2_HUMAN 1934.4+590.4 1049.0+259.7 0.54 0.007 GuHCl
Dermatopontin DERM_HUMAN 425.7+103.5 129.9+54.9 0.31 ,0.001 GuHCl
Fibromodulin FMOD_HUMAN 56.6+32.2 12.6+9.7 0.22 0.009 GuHCl
Fibronectin FINC_HUMAN 103.1+56.2 31.8+14.9 0.31 0.013 NaCl
Galectin-3-binding protein LG3BP_HUMAN 2.9+1.3 0.6+0.9 0.19 0.004 GuHCl
Gelsolin GELS_HUMAN 97.1+58.3 159.7+23.7 1.65 0.035 GuHCl
Laminin subunit beta-1 LAMB1_HUMAN 2.9+0.9 4.9+1.4 1.67 0.018 GuHCl
Laminin subunit beta-2 LAMB2_HUMAN 105.9+40.9 171.5+45.6 1.62 0.026 GuHCl
Laminin subunit gamma-1 LAMC1_HUMAN 80.9+34.9 156.4+31.5 1.93 0.003 GuHCl
Latent-TGFb-binding protein 2 LTBP2_HUMAN 4.8+2.0 1.5+1.1 0.32 0.007 GuHCl
Lumican LUM_HUMAN 1577.2+436.8 979.7+411.1 0.62 0.035 GuHCl
Metalloproteinase inhibitor 3 TIMP3_HUMAN 3.3+2.4 0.1+0.4 0.05 0.010 GuHCl
Mimecan MIME_HUMAN 633.1+89.0 293.2+78.2 0.46 ,0.001 GuHCl
Mimecan MIME_HUMAN 12.1+7.9 4.6+1.7 0.38 0.047 NaCl
Nidogen-2 NID2_HUMAN 29.7+14.7 14.3+3.2 0.48 0.031 GuHCl
Prolargin PRELP_HUMAN 1203.6+293.0 484.1+261.4 0.40 0.001 GuHCl
Prosaposin SAP_HUMAN 3.5+1.1 2.0+1.0 0.58 0.040 GuHCl
Protein S100-A10 S10AA_HUMAN 18.3+5.9 8.2+6.2 0.45 0.017 GuHCl
Serine protease HTRA1 HTRA1_HUMAN 29.6+13.6 4.0+5.3 0.14 0.002 GuHCl
Serum amyloid P-component SAMP_HUMAN 107.2+41.8 10.7+12.5 0.10 ,0.001 GuHCl
Target of Nesh-SH3 TARSH_HUMAN 155.6+86.9 72.7+27.1 0.47 0.050 GuHCl
TGFß-induced protein ig-h3 BGH3_HUMAN 15.2+4.0 79.6+39.4 5.25 0.003 NaCl
Thrombospondin-1 TSP1_HUMAN 16.7+10.4 36.1+8.1 2.17 0.005 NaCl
Tubulointerstitial nephritis antigen-like TINAL_HUMAN 122.0+35.5 58.8+21.6 0.48 0.004 GuHCl
Vitronectin VTNC_HUMAN 23.3+5.5 4.4+3.6 0.19 ,0.001 GuHCl
von Willebrand factor A domain-containing protein 1 VWA1_HUMAN 13.9+9.6 4.6+2.9 0.33 0.048 GuHCl
Average+ standard deviation (Av+ SD) based on total ion current (TIC × 10 to the power of 6).
P-values were derived from unpaired Student’s t-tests with unequal variance (Note that every time protein expression in the majority of samples from 1 of the 2 groups compared was
undetectable, the t-test was not performed; hyphens (-) denote these proteins without detection in one of the groups). NA denotes ‘not applicable’.
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was seen throughout the vessel wall (Figure 6C and see Supplementary
material online, Figure S6). Gene expression analysis showed that both
chymase and tryptase b1 were expressed in tissue samples but not in
cultured human venous SMCs (Figure 6D, top panel), even when stimu-
lated with TGFb-1, TNFa, and Ang II (data not shown). Instead, the in-
creased abundance of these mast cell proteases in VSV was paralleled
by an increase in CD68, a marker for the various cells of the macro-
phage lineage, and a decrease of a-SMA (Figure 6D, lower panel; see
Supplementary material online, Figure S6 for quantification by
densitometry).
To investigate the effect in venous tissue of tryptase b1 and chymase,
NSV macroscopically free of vascular disease were subjected to an
overnight digestion with tryptase b1 and chymase. NSV incubated in
enzyme buffer-only were used as controls. The proteins released after
digestion were analysed by gel-LC-MS/MS (see Supplementary material
online, Figure S7). Extracellular proteins detected after chymase and
tryptase b1 digestion of NSV are listed in Supplementary material on-
line, Table S8 and Table S9, respectively. The effect of the treatment
with tryptase b1 and chymase on the distribution of various protease
targets is presented in the Supplementary material online, Figure S8.
The in-gel approach allowed assignments of fragments from ECM pro-
teins identified in bands lower than their expected molecular weights
(Mw) resulting in higher spectral counts or a shift in their Mw distribu-
tion. Only for small proteins like galectin-1 (14 kDa), fragments were
not detected upon digestion, probably due to migration ahead of the
gel front. Notably, the effect of tryptase b1 on the venous ECM was
generally more pronounced (see Supplementary material online, Table
S10). Basement membrane (BM)-associated proteins, such as collagen
VI, perlecan, and tenascins, however, were predominantly affected by
digestion with chymase. In contrast, no effect was observed on
CO1A1 and CO1A2, suggesting that increased chymase levels cannot
attenuate collagen I accumulation in VSV. For independent validation,
we performed immunoblotting for tenascin C on the conditioned
medium after digestion with tryptase b1 and chymase. Degradation
was observed following incubation with both proteases (Figure 6E,
left panel), and a similar degradation pattern was observed in VSV
(Figure 6E, right panel). Thus, besides changes in gene expression,
remodelling in VSV involves proteolysis of ECM components.
4. Discussion
In continuation of our previous work on applying proteomics to study
the cardiovascular ECM,5– 8 this is the first proteomics analysis of the
ECM in human veins that describes the remodelling process of the
venous ECM, a critical step in the development of varicosis. The key
proteomic findings are summarized in Figure 7.
4.1 ECM remodelling in veins
Venous hypertension in the hepatic, splanchnic, and peripheral circula-
tion affects a large population of patients presenting with liver, renal,
and cardiovascular disease. Although the causes of venous hyperten-
sion may be multifactorial, epigenetic factors at the level of the venous
wall may also be involved in mediating susceptibility. Varicose veins are
among the most prevalent medical problems today with worldwide
prevalence estimates of up to 73% in females and 56% in males.11 It
is associated with significant morbidity and has a considerable econom-
ic impact causing an estimated loss of 2 million workdays and costing
$3 billion to treat in the USA alone.12 The pathogenesis of varicose
veins is associated with many predisposing factors including pregnancy,
trauma, obesity, and prolonged standing. However, it is becoming
increasingly apparent that its development is more complex, likely
Figure 2 Proteomics revealed a distinct ECM composition in NSV
and VSV. Heat maps for NaCl and GuHCl extracts in NSV and VSV
based on normalized protein abundance to allow for representation
of proteins with different abundances (n ¼ 6 per group). Underlined
proteins were validated by either MRM or western blot analysis. Pro-
teins in bold were analysed at the transcriptional level by RT–qPCR.
Proteins without detection for one of the groups are labelled with an
asterisk (*). For detailed information, refer to Table 1. Statistical signifi-
cance (P, 0.05) was calculated using Student’s t-tests.
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involving inborn, epigenetic, or local genetic traits that probably play
key roles in increasing susceptibility to developing varicose veins.3
Until now, a comprehensive analysis of ECM components compris-
ing NSV and VSV has not been performed. In recent years, our group
has used proteomics to study ECM remodelling in different cardiovas-
cular diseases, including in aortic specimen.5,6,13 Compared with
other tissues, the decellularization step is a key to reduce complexity
and minimize carryover from cell- and blood-derived proteins in
cardiovascular tissues.14 A caveat of the gel-LC-MS/MS approach is
the fact that very large ECM proteins may not migrate into the gel.15
On the other hand, the presence of these high Mw proteins can
mask the presence of less abundant ECM proteins since they generate
far more tryptic peptides than low Mw proteins. Similarly, in the pre-
sent study, both approaches revealed interesting and complimentary
protein changes that were validated by independent techniques,
including western blot and MRM analysis.
Figure 3 Alterations in collagen composition in VSV. (A) Abundance of fibril-forming collagens compared with other families of collagens detected in
GuHCl extracts from NSV (n ¼ 6) and VSV (n ¼ 6). For visualization purposes, the total ion current (TIC) for CO5A1 and CO5A2 was scaled up 10-fold
in the left panel. CO6A1 and CO6A3 were scaled down five-fold in the right panel. (B) Different chains form cross-linked collagen polymers within
vascular tissues. Scatter plots for protein abundance (expressed as TIC) demonstrate high correlation for different chains of the same collagen. (C ) Pro-
portion of hydroxylated prolines in collagens from NSV compared with VSV. A much higher proportion is observed for fibril-forming collagens com-
pared with other families. Dysregulation in collagen content in VSV did not affect the rate of collagen hydroxylation. Statistical significance was calculated
using Student’s t-tests. * denotes P, 0.05, **P, 0.01, ***P, 0.001.
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In VSV, the perivascular space is surrounded by ECM proteins. This
perivascular cuff is an initial response to an increased mechanical load
and is accompanied by collagen deposition. However, the collagen
fibres show abnormal distribution and morphology. Immunohisto-
chemical analyses demonstrated that VSV had irregular collagen
fibrillogenesis and redundant lamellae of BM material.16 Our proteo-
mics results corroborate these histological findings by demonstrating
an increase in collagen I chains and laminins in VSV. Other BM proteins
and collagen-binding proteins required for assembly, size, and structure
of collagen fibres showed a marked reduction in chronic venous
Figure 4 Targeted proteomics (MRM analysis) to validate the proteomics findings. (A) MRM assays were used to validate differential expression of
additional ECM proteins in NSV (n ¼ 6) and VSV (n ¼ 6). LAMB2, laminin subunit b2; LAMC1, laminin subunit g1; PGS2, decorin; ASPN, asporin; TINAL,
tubulointerstitial nephritis antigen-like protein; DERM, dermatopontin; VTNC, vitronectin; PGCA, aggrecan; CO1A1 and CO1A2, collagen a1 (I) and
a2(I) chains. (B) MRM analysis for two peptides of the same protein demonstrated high correlation, which is an indication of robustness of our measure-
ments. Only aggrecan (PGCA) showed poor correlation. Statistical significance was calculated using Student’s t-tests. * denotes P, 0.05, **P, 0.01,
***P, 0.001.
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insufficiency. TGFb-induced protein ig-h3, a downstream marker for
TGFb activity, and thrombospondin-1, a key activator of TGFb, were
increased confirming previous reports of exacerbated levels of local
TGFb in VSV.17 In addition, our proteomics study revealed a decrease
in SLRPs.18 All detected SLRPs in venous vessels (decorin, mimecan, bi-
glycan, fibromodulin, prolargin, lumican, asporin, and podocan) have
horseshoe shapes and embrace collagen fibres to ensure appropriate
calibre, shape, and disposition.19 Furthermore, decorin, biglycan,
fibromodulin, and asporin bind TGFb, repressing the activation of
pro-fibrotic pathways.18 Reduced levels of SLRPs with TGFb-binding
activity and of TGFb-sequestering proteins such as cartilage intermedi-
ate layer protein 1 (CILP1, Figure 2) support the notion of exacerbated
TGFb activity in chronic venous insufficiency.17 Moreover, our data
show that in venous SMCs, expression of other SLRPs such as mimecan
is responsive not only to the pro-fibrotic cytokine TGFb-1, but also to
the pro-inflammatory cytokine TNFa, which is known to be elevated in
patients with venous ulcers.20
4.2 Vascular proteases
MMPs with their broad substrate specificity8 have been identified as key
drivers of ECM degradation, in particular during the earlier stages of
venous remodelling.21 Decreased protein levels of TIMP3 (i.e. a broad
spectrum matrix-associated metalloproteinase inhibitor) detected in
our proteomics analysis of the GuHCl extracts (Table 1), support the
concept of increased proteolytic activity in venous hypertension.
TIMP3, however, was not altered at the transcript level (Figure 6B)
but has previously been implicated in preserving the vascular ECM in
arterial hypertension.22 Additional metalloproteinases include aggreca-
nases from the ADAMTS family. The ADAMTS enzymes are secreted,
multi-domain zinc metalloendopeptidases with diverse roles in physio-
pathological remodelling, inflammation, and vascular biology.23
Interestingly, aggrecan, a major ECM component of cartilage, has pre-
viously been identified in aortic tissue.7 Negatively charged glycans on
the surface of aggrecan attract water and therefore confer resistance to
compression. To our knowledge, the present study is the first to report
the identification of aggrecan in venous tissue. Expression of aggrecan
in VSV was reduced at the protein and transcript levels in comparison
to NSV. The loss of aggrecan was accompanied by a reduction of
aggrecanase expression (ADAMTS1 and ADAMTS4).
Our proteomics analyses returned additional proteases, including
chymase and tryptase b1. These serine proteases are commonly attrib-
uted to secretory granules of mast cells and promote inflammation and
ECM remodelling.24,25 Although one study reported no significant
difference in the mean mast cell density in the wall of varicose and
non-dilated veins,26 several groups have demonstrated that mast cells
are a predominant cell type in VSV.27 Intriguingly, chymase staining in
VSV rarely co-localised with tryptase b1 (Figure 6C). The presence of
a vascular SMC-expressed chymase has previously been reported in ar-
teries of spontaneously hypertensive rats.28,29 While the observed
staining pattern was suggestive of an ubiquitous presence of chymase
in VSV, including SMCs, the lack of chymase expression in cultured ven-
ous human SMCs is evidence to the contrary, and stimulation with
TGFb-1, Ang II, and TNFa failed to induce expression (data not
shown). Although we observed increased abundance of the macro-
phage lineage marker CD68 in VSV, a recent paper by Shankman
et al.30 demonstrated that expression of CD68 and other non-SMC
markers can be induced in SMCs within atherosclerotic plaques.
Thus, lineage tracing rather than co-staining is required to establish
cellular origin in diseased tissues.
Figure 5 Discrepancies between protein abundance in the ECM
and corresponding gene expression levels. (A) Relative gene expres-
sion of ECM targets (Figure 2) in NSV and VSV. Protein abundance le-
vels detected after proteomics analysis of NSV and VSV are shown for
comparison (left plot). To compare transcripts and proteins with dis-
parate basal values, protein abundance and gene expression levels
were set to ‘1’ for NSV. Horizontal lines represent the SEM for
NSV and VSV (n ¼ 6 per group). Black squares represent significant
(P, 0.05) changes as determined by Student’s t-test. (B) Immuno-
blotting for mimecan (MIME), fibronectin (FINC), TGFb-induced pro-
tein ig-h3 (BGH3), gelsolin (GELS), and decorin (PGS2). (C) Venous
human SMCs from six donor patients incubated with TGFb-1 and
TNFa showed reduced mimecan expression. Incubation with Ang II
did not affect mimecan expression. Levels of expression for unstimu-
lated control cells are represented by the dashed line. Statistical sig-
nificance was calculated using an ANOVA test with Dunnett’s
correction. *** denotes P, 0.001.
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Figure 6 Protease activity as contributor to ECM remodelling in VSV. (A) Ct values for different vascular proteases in NSV (n ¼ 6) and venous SMCs
(n ¼ 6) as determined by RT–qPCR. A Ct value .35 was considered undetectable. ADAMTS, a disintegrin metalloproteinase with thrombospondin
domains; HTRA1, serine protease HTRA1; MMP, matrix metalloproteinase, TIMP, tissue inhibitor of matrix metalloproteinase; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase. (B) A down-regulation for the aggrecanases ADAMTS1 and ADAMTS4 was observed in VSV. Data points
are averages+ SEM. Black squares represent significant (P, 0.05) changes as determined by Student’s t-test. (C) Distribution of chymase and tryptase
b1 in NSV and VSV. Note the extensive cellular staining for chymase. A patchy, less prominent distribution was observed for tryptase b1. (D) Chymase
(CMA1) and tryptase b1 (TRYB) were expressed in vein tissues but were undetectable in cultured venous SMCs. Western blot analysis of NSV and VSV
confirmed higher abundance of chymase and tryptase b1 in VSV. This paralleled an increased detection for CD68 and decrease of a-SMA. (E) NSV
samples (n ¼ 5) were split into two halves and incubated with the two proteases or the corresponding buffers only, before western blot analysis.
An example is shown for two experiments. Incubation with the proteases led to detection of a degradation pattern in tenascin C (TNC). Boxed numbers
indicate the expected size (kDa) for the full-length protein. Protein degradation products for tenascin were observed in VSV similar to the observations in
the adjacent panel. Ponceau S staining was used as a loading control.
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Apart from a chymase-dependent Ang II-generating pathway in the
vessel wall,28,31 there are several other mechanisms by which chymases
may impact on blood vessels and in particular affect SMCs.32 For ex-
ample, Leskinen et al.33,34 demonstrated that chymase is pro-apoptotic
for vascular SMCs by degrading the pericellular ECM component fibro-
nectin, causing disruption of focal adhesion complexes and Akt depho-
sphorylation, which are necessary for cell adhesion and survival.
Similarly, we have observed fibronectin degradation and preferential
release of BM proteins by chymase digestion of NSV. On the other
hand, there are endogenous protease inhibitors in the interstitial fluid
that would inhibit chymase activity.35 The importance of proteolytic ac-
tivity for the wall stress-induced maladaptive venous remodelling has
been highlighted by a recent study; inhibition of the 26S proteasome
using bortezomib led to a stabilization of the quiescent SMC pheno-
type. Bortezomib inhibits the chymotrypsin-like activity of the 26S pro-
teasome, and transdermal administration diminished venous SMC
proliferation by 80% and inhibited varicose-like venous remodelling
in a mouse model.36 Notably, chymases have chymotrypsin-like
substrate specificity.
4.3 Strengths and limitations
A strength of the study is the use of well-characterized patient samples.
A caveat of working with patient specimens is that only end-stage dis-
ease can be assessed. Therefore, future studies to clarify the temporal
expression and activity patterns of vascular proteases will be required.
To that end, animal models offer unique insights into disease progres-
sion. Although mast cells have been shown to play detrimental roles in
the pathogenesis of both atherosclerosis37 and abdominal aortic aneur-
ysm,38 mast cell chymase can also prevent an exaggerated SMC expan-
sion.25,34 Further studies are required to explore the role and cellular
localization of chymase in VSV. Moreover, our proteomics workflow
targets extracellular proteins, but released proteins do not necessarily
reflect intracellular protein concentrations. For example, increased
levels of cathepsins have been observed in VSV.39
In conclusion, varicosis is intimately related to dynamic changes in
the vascular ECM and its associated proteins. The present proteomics
study provides the first comprehensive analysis of the ECM remodelling
processes in response to venous hypertension.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
Acknowledgements
We thank Dr Athanasios Didangelos for technical assistance and
Dr Sarah Langley for help with statistical analysis.
Conflict of interest: none declared.
Funding
This work was supported by the American College of Phlebology (R.O.)
and the National Institute for Health Research (NIHR) Biomedical Re-
search Centre based at Guy’s and St Thomas’ NHS Foundation Trust and
King’s College London in partnership with King’s College Hospital and an
excellence initiative (Competence Centers for Excellent Technologies -
COMET) of the Austrian Research Promotion Agency FFG: ‘Research Cen-
ter of Excellence in Vascular Ageing – Tyrol, VASCage’ (K-Project Nr.
843536) funded by the BMVIT, BMWFW, the Wirtschaftsagentur Wien,
and the Standortagentur Tirol. H.A. is funded by Massachusetts General
Hospital, Department of Surgery, Division of Vascular and Endovascular
Surgery, Henry & Nod Meyer Research Fund. M.M. is a Senior Fellow of
the British Heart Foundation.
References
1. Oklu R, Habito R, Mayr M, Deipolyi AR, Albadawi H, Hesketh R, Walker TG,
Linskey KR, Long CA, Wicky S, Stoughton J, Watkins MT. Pathogenesis of varicose
veins. J Vasc Interv Radiol 2012;23:33–39.
2. Hamdan A. Management of varicose veins and venous insufficiency. JAMA 2012;308:
2612–2621.
3. Bharath V, Kahn SR, Lazo-Langner A. Genetic polymorphisms of vein wall remodeling in
chronic venous disease: a narrative and systematic review. Blood 2014;124:1242–1250.
4. Barallobre-Barreiro J, Didangelos A, Yin X, Dome´nech N, Mayr M. A sequential extrac-
tion methodology for cardiac extracellular matrix prior to proteomics analysis.Methods
Mol Biol 2013;1005:215–223.
5. Barallobre-Barreiro J, Didangelos A, Schoendube FA, Drozdov I, Yin X,
Ferna´ndez-Caggiano M, Willeit P, Puntmann VO, Aldama-Lo´pez G, Shah AM,
Dome´nech N, Mayr M. Proteomics analysis of cardiac extracellular matrix remodeling
in a porcine model of ischemia/reperfusion injury. Circulation 2012;125:789–802.
6. Didangelos A, Yin X, Mandal K, Saje A, Smith A, Xu Q, Jahangiri M, Mayr M. Extracellular
matrix composition and remodeling in human abdominal aortic aneurysms: a proteo-
mics approach. Mol Cell Proteomics 2011;10:M111. 008128.
7. Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M. Proteomics character-
ization of extracellular space components in the human aorta. Mol Cell Proteomics 2010;
9:2048–2062.
Figure 7 Summary of the proteomics findings. ECM remodelling is a hallmark of VSV formation. Differences detected in the present study reflect
a combination of changes in protein abundance, gene expression, and proteolytic activity.
Extracellular matrix of veins 429
8. Stegemann C, Didangelos A, Barallobre-Barreiro J, Langley S, Mandal K, Jahangiri M,
Mayr M. Proteomic identification of matrix metalloproteinase substrates in the human
vasculature. Circ Cardiovasc Genet 2013;6:106–117.
9. Pokidysheva E, Boudko S, Vranka J, Zientek K, Maddox K, Moser M, Fa¨ssler R, Ware J,
Ba¨chinger HP. Biological role of prolyl 3-hydroxylation in type IV collagen. Proc Natl
Acad Sci USA 2014;111:161–166.
10. Yamauchi M, Sricholpech M. Lysine post-translational modifications of collagen. Essays
Biochem 2012;52:113–133.
11. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic
venous insufficiency and varicose veins. Ann Epidemiol 2005;15:175–184.
12. McGuckin M, Waterman R, Brooks J, Cherry G, Porten L, Hurley S, Kerstein MD.
Validation of venous leg ulcer guidelines in the United States and United Kingdom.
Am J Surg 2002;183:132–137.
13. Drozdov I, Didangelos A, Yin X, Zampetaki A, Abonnenc M, Murdoch C, Zhang M,
Ouzounis CA, Mayr M, Tsoka S, Shah AM. Gene network and proteomic analyses of
cardiac responses to pathological and physiological stress. Circ Cardiovasc Genet 2013;
6:588–597.
14. Wilson R, Norris EL, Brachvogel B, Angelucci C, Zivkovic S, Gordon L, Bernardo BC,
Stermann J, Sekiguchi K, Gorman JJ, Bateman JF. Changes in the chondrocyte and extra-
cellular matrix proteome during post-natal mouse cartilage development. Mol Cell Pro-
teomics 2012;11:M111. 014159.
15. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB. The interaction of versican with its binding
partners. Cell Res 2005;15:483–494.
16. Higley H, Ksander G, Gerhardt C, Falanga V. Extravasation of macromolecules and pos-
sible trapping of transforming growth factor-b in venous ulceration. Br J Dermatol 1995;
132:79–85.
17. Badier-Commander C, Couvelard A, Henin D, Verbeuren T, Michel JB, Jacob MP.
Smooth muscle cell modulation and cytokine overproduction in varicose veins. An
in situ study. J Pathol 2001;193:398–407.
18. Merline R, Schaefer RM, Schaefer L. The matricellular functions of small leucine-rich
proteoglycans (SLRPs). J Cell Commun Signal 2009;3:323–335.
19. Chen S, Birk DE. The regulatory roles of small leucine–rich proteoglycans in extracel-
lular matrix assembly. FEBS J 2013;280:2120–2137.
20. Murphy MA, Joyce WP, Condron C, Bouchier-Hayes D. A reduction in serum cytokine
levels parallels healing of venous ulcers in patients undergoing compression therapy.
Eur J Vasc Endovasc Surg 2002;23:349–352.
21. Kucukguven A, Khalil RA. Matrix metalloproteinases as potential targets in the venous
dilation associated with varicose veins. Curr Drug Targets 2013;14:287.
22. Basu R, Lee J, Morton JS, Takawale A, Fan D, Kandalam V, Wang X, Davidge ST,
Kassiri Z. TIMP3 is the primary TIMP to regulate agonist-induced vascular remodelling
and hypertension. Cardiovasc Res 2013;98:360–371.
23. Kelwick R, Desanlis I, Wheeler GN, Edwards DR. The ADAMTS (A Disintegrin and
Metalloproteinase with Thrombospondin motifs) family. Genome Biol 2015;16:113.
24. Kinoshita M, Okada M, Hara M, Furukawa Y, Matsumori A. Mast cell tryptase in mast
cell granules enhances MCP-1 and interleukin-8 production in human endothelial cells.
Arterioscler Thromb Vasc Biol 2005;25:1858–1863.
25. Leskinen M, Wang Y, Leszczynski D, Lindstedt KA, Kovanen PT. Mast cell chymase
induces apoptosis of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001;
21:516–522.
26. Haviarova´ Z, Weismann P, Pavlı´kova´ D, Durdı´k Sˇ, Kova´cˇ P, Sˇtvrtinova´ V, Mra´z P. Mast
cell infiltration in the wall of varicose veins. Acta Histochem 2002;104:357–360.
27. Sayer G, Smith P. Immunocytochemical characterisation of the inflammatory cell
infiltrate of varicose veins. Eur J Vasc Endovasc Surg 2004;28:479–483.
28. Guo C, Ju H, Leung D, Massaeli H, Shi M, Rabinovitch M. A novel vascular smooth
muscle chymase is upregulated in hypertensive rats. J Clin Invest 2001;107:703.
29. Ju H, Gros R, You X, Tsang S, Husain M, Rabinovitch M. Conditional and targeted over-
expression of vascular chymase causes hypertension in transgenic mice. Proc Natl Acad
Sci USA 2001;98:7469–7474.
30. Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM,
Swiatlowska P, Newman AA, Greene ES, Straub AC, Isakson B, Randolph GJ,
Owens GK. KLF4-dependent phenotypic modulation of smooth muscle cells has a
key role in atherosclerotic plaque pathogenesis. Nat Med 2015;21:628–637.
31. Miyazaki M, Takai S, Jin D, Muramatsu M. Pathological roles of angiotensin II produced
by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol
Ther 2006;112:668–676.
32. Waern I, Jonasson S, Hjoberg J, Bucht A, A˚brink M, Pejler G, Wernersson S. Mouse
mast cell protease 4 is the major chymase in murine airways and has a protective
role in allergic airway inflammation. J Immunol 2009;183:6369–6376.
33. Leskinen MJ, Heikkila¨ HM, Speer MY, Hakala JK, Laine M, Kovanen PT, Lindstedt KA.
Mast cell chymase induces smooth muscle cell apoptosis by disrupting
NF-kB-mediated survival signaling. Exp Cell Res 2006;312:1289–1298.
34. Leskinen MJ, Lindstedt KA, Wang Y, Kovanen PT, Lindstedt KA. Mast cell chymase in-
duces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation
and disruption of focal adhesions. Arterioscler Thromb Vasc Biol 2003;23:238–243.
35. Kokkonen JO, Lindstedt KA, Kovanen PT. Role for chymase in heart failure angiotensin
II-dependent or-independent mechanisms? Circulation 2003;107:2522–2524.
36. Pfisterer L, Meyer R, Feldner A, Drews O, Hecker M, Korff T. Bortezomib protects
from varicose-like venous remodeling. FASEB J 2014;28:3518–3527.
37. Metzler B, Xu Q. The role of mast cells in atherosclerosis. Int Arch Allergy Immunol 1997;
114:10–14.
38. Sun J, Zhang J, Lindholt JS, Sukhova GK, Liu J, He A, A˚brink M, Pejler G, Stevens RL,
Thompson RW, Ennis TL, Gurish MF, Libby P, Shi G-P. Critical role of mast cell chymase
in mouse abdominal aortic aneurysm formation. Circulation 2009;120:973–982.
39. Xu N, Zhang Y-Y, Lin Y, Bao B, Zheng L, Shi G-P, Liu J. Increased levels of lysosomal
cysteinyl cathepsins in human varicose veins: a histology study. Thromb Haemost
2014;111:333–344.
J. Barallobre-Barreiro et al.430
